Synergistic Effect of Calcineurin Inhibitors and Fluconazole against Candida albicans Biofilms
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Calcineurin is a Ca 2+ -calmodulin-activated serine/threonine-specific protein phosphatase that governs multiple aspects of fungal physiology, including cation homeostasis, morphogenesis, antifungal drug susceptibility, and virulence. Growth of Candida albicans planktonic cells is sensitive to the calcineurin inhibitors FK506 and cyclosporine A (CsA) in combination with the azole antifungal fluconazole. This drug synergism is attributable to two effects: first, calcineurin inhibitors render fluconazole fungicidal rather than simply fungistatic, and second, membrane perturbation by azole inhibition of ergosterol biosynthesis increases intracellular calcineurin inhibitor concentrations. C. albicans cells in biofilms are up to 1,000-fold more resistant to fluconazole than planktonic cells. In both in vitro experiments and in an in vivo rat catheter model, C. albicans cells in biofilms were resistant to individually delivered fluconazole or calcineurin inhibitors but exquisitely sensitive to the combination of FK506-fluconazole or CsA-fluconazole. C. albicans strains lacking FKBP12 or expressing a dominant FK506-resistant calcineurin mutant subunit (Cnb1-1) formed biofilms that were resistant to FK506-fluconazole but susceptible to CsA-fluconazole, demonstrating that drug synergism is mediated via direct calcineurin inhibition. These findings reveal that calcineurin contributes to fluconazole resistance of biofilms and provide evidence that synergistic drug combinations may prove efficacious as novel therapeutic interventions to treat or prevent biofilms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hsp90 and calcineurin are well known to affect fungal drug responses, including the cidality of azoles 26,32,42,43,70,71 .”
From Antifungal tolerance is a subpopulation effect distinct from resistance and is associated with persistent candidemia (2018) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous findings have indicated little or no effect for treatment of mature biofilms when FLU is used in combination with other antifungals, including AmB and CAS [10], whereas synergistic effects (similar to the enhanced effect reported in this study) have been observed when FLU is combined with calcium channel inhibitors [11] and doxycycline [12], among others.”
From In vitro analysis of flufenamic acid activity against Candida albicans biofilms (2014) · cites this paper as [11]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Secular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980-1990
Sague, C. M. B., Jarvis, W. R., & System, N. N. I. S. (1993) · Journal of Infectious Diseases · doi:10.1093/infdis/167.5.1247 · Cited by 1,140
Standardized Method for In Vitro Antifungal Susceptibility Testing of Candida albicans Biofilms
Ramage, G., Vande Walle, K., Wickes, B. L., & López-Ribot, J. L. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.9.2475-2479.2001 · Cited by 753
Mukherjee, P. K., Chandra, J., Kuhn, D. M., & Ghannoum, M. A. (2003) · Infection and Immunity · doi:10.1128/iai.71.8.4333-4340.2003 · Cited by 511 · cited 2×
“albicans biofilm resistance to fluconazole is considered multifactorial, encompassing contributions of cell density, impermeability of drugs through the extracellular matrix, activation of multidrug efflux pumps, increases in cellular -1,3 glucan levels, and decreases in sterol levels (5, 20, 22, 26).”
BackgroundNosocomial Candidemia: Risk Factors and Attributable Mortality
Wenzel, R. P. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.6.1531 · Cited by 502 · cited 1×
“albicans can enter the bloodstream to cause serious systemic invasive disease (6, 38).”
BackgroundPutative Role of β-1,3 Glucans in Candida albicans Biofilm Resistance
Nett, J., Lincoln, L., Marchillo, K., Massey, R., Holoyda, K., Hoff, B., VanHandel, M., & Andes, D. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01056-06 · Cited by 407 · cited 3×
“A recent report also demonstrated that cell wall -1,3 glucan levels contribute to biofilm resistance to fluconazole (22).”
BackgroundMethodSelf-citationBaillie, G. S. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.3.397 · Cited by 389
Andes, D., Nett, J., Oschel, P., Albrecht, R., Marchillo, K., & Pitula, A. (2004) · Infection and Immunity · doi:10.1128/iai.72.10.6023-6031.2004 · Cited by 389
Self-citationSanglard, D., Ischer, F., Marchetti, O., Entenza, J., & Bille, J. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03495.x · Cited by 350
Calcineurin is essential for survival during membrane stress in Candida albicans
Cruz, M. C., Goldstein, A. L., Blankenship, J. R., Del Poeta, M., Davis, D., Cardenas, M. E., Perfect, J. R., McCusker, J. H., & Heitman, J. (2002) · The EMBO Journal · doi:10.1093/emboj/21.4.546 · Cited by 342 · cited 15×
“albicans, calcineurin is required for survival in serum, virulence, and resistance to azole antifungals, in part via its downstream target, Crz1 (7, 9, 11, 15).”
BackgroundInfluentialSelf-citationBiochemical Targets for Antifungal Azole Derivatives: Hypothesis on the Mode of Action
Vanden Bossche, H. (1985) · Current Topics in Medical Mycology · doi:10.1007/978-1-4613-9547-8_12 · Cited by 321
Cited by
Drug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642
Efflux-Mediated Antifungal Drug Resistance
Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Baret, P. V., Keniya, M. V., Tanabe, K., Niimi, M., Goffeau, A., & Monk, B. C. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00051-08 · Cited by 608
Ramage, G., Rajendran, R., Sherry, L., & Williams, C. (2012) · International Journal of Microbiology · doi:10.1155/2012/528521 · Cited by 583
“Calcineurin has also been implicated in mediating resistance to the azoles in both in vitro and in vivo models of biofilm formation [176].”
BackgroundRegulatory circuitry governing fungal development, drug resistance, and disease.
Shapiro, R. S., Robbins, N., & Cowen, L. E. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00045-10 · Cited by 576
Mechanisms of Candida Biofilm Drug Resistance
Taff, H. T., Mitchell, K. F., Edward, J. A., & Andes, D. R. (2013) · Future Microbiology · doi:10.2217/fmb.13.101 · Cited by 422
“identified a role for calcineurin, a Ca calmodulin-activated serine/threonine-specific protein phosphatase important for homeostasis, morphogenesis and virulence [113].”
BackgroundSelf-citationHsp90 Governs Dispersion and Drug Resistance of Fungal Biofilms
Robbins, N., Uppuluri, P., Nett, J., Rajendran, R., Ramage, G., Lopez-Ribot, J. L., Andes, D., & Cowen, L. E. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002257 · Cited by 291
Self-citationA Candida Biofilm-Induced Pathway for Matrix Glucan Delivery: Implications for Drug Resistance
Taff, H. T., Nett, J. E., Zarnowski, R., Ross, K. M., Sanchez, H., Cain, M. T., Hamaker, J., Mitchell, A. P., & Andes, D. R. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002848 · Cited by 291
“A parallel study of cell wall function was performed to assess the potential impact of the glucan modifying genes on the cell wall integrity pathway that has been shown to contribute to the biofilm formation and drug resistance mechanism [36,37].”
BackgroundSelf-citationRosenberg, A., Ene, I. V., Bibi, M., Zakin, S., Segal, E. S., Ziv, N., Dahan, A. M., Colombo, A. L., Bennett, R. J., & Berman, J. (2018) · Nature Communications · doi:10.1038/s41467-018-04926-x · Cited by 270
Antifungal Drugs: The Current Armamentarium and Development of New Agents
Robbins, N., Wright, G. D., & Cowen, L. E. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.funk-0002-2016 · Cited by 271
Recent insights into Candida albicans biofilm resistance mechanisms
Mathé, L., & Van Dijck, P. (2013) · Current Genetics · doi:10.1007/s00294-013-0400-3 · Cited by 271
Antifungal Peptides as Therapeutic Agents
Fernández de Ullivarri, M., Arbulu, S., Garcia-Gutierrez, E., & Cotter, P. D. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00105 · Cited by 264
Antifungal drug-resistance mechanisms in Candida biofilms
Kaur, J., & Nobile, C. J. (2023) · Current Opinion in Microbiology · doi:10.1016/j.mib.2022.102237 · Cited by 261
Combinatorial strategies for combating invasive fungal infections
Spitzer, M., Robbins, N., & Wright, G. D. (2017) · Virulence · doi:10.1080/21505594.2016.1196300 · Cited by 218
Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata
Singh-Babak, S. D., Babak, T., Diezmann, S., Hill, J. A., Xie, J. L., Chen, Y.-L., Poutanen, S. M., Rennie, R. P., Heitman, J., & Cowen, L. E. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002718 · Cited by 205
Self-citationMechanistic Understanding of Candida albicans Biofilm Formation and Approaches for Its Inhibition
Atriwal, T., Azeem, K., Husain, F. M., Hussain, A., Khan, M. N., Alajmi, M. F., & Abid, M. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.638609 · Cited by 201
Inhibitory Effect of Sophorolipid on Candida albicans Biofilm Formation and Hyphal Growth
Haque, F., Alfatah, M., Ganesan, K., & Bhattacharyya, M. S. (2016) · Scientific Reports · doi:10.1038/srep23575 · Cited by 189
Antifungals: Mechanism of Action and Drug Resistance
Prasad, R., Shah, A. H., & Rawal, M. K. (2016) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-25304-6_14 · Cited by 183
Antifungal therapy with an emphasis on biofilms
Pierce, C. G., Srinivasan, A., Uppuluri, P., Ramasubramanian, A. K., & López-Ribot, J. L. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.08.008 · Cited by 173
Self-citationSynergistic combinations of antifungals and anti-virulence agents to fight against Candida albicans
Cui, J., Ren, B., Tong, Y., Dai, H., & Zhang, L. (2015) · Virulence · doi:10.1080/21505594.2015.1039885 · Cited by 171
Nett, J. E., Sanchez, H., Cain, M. T., Ross, K. M., & Andes, D. R. (2011) · Eukaryotic Cell · doi:10.1128/ec.05126-11 · Cited by 168
“Subsequent studies have suggested that biofilm drug resistance is multifactorial, with contributions from biofilm-specific processes as well (6, 18, 20, 28, 34, 43, 47, 50).”
BackgroundSelf-citationAntifungal drug resistance of oral fungi
Niimi, M., Firth, N. A., & Cannon, R. D. (2010) · Odontology · doi:10.1007/s10266-009-0118-3 · Cited by 166
Development and Validation of an In Vivo Candida albicans Biofilm Denture Model
Nett, J. E., Marchillo, K., Spiegel, C. A., & Andes, D. R. (2010) · Infection and Immunity · doi:10.1128/iai.00480-10 · Cited by 161
Self-citationHolmes, A. R., Lin, Y.-H., Niimi, K., Lamping, E., Keniya, M., Niimi, M., Tanabe, K., Monk, B. C., & Cannon, R. D. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00463-08 · Cited by 159
Pierce, C. G., & Lopez-Ribot, J. L. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.807245 · Cited by 158
Nett, J. E., Cain, M. T., Crawford, K., & Andes, D. R. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02273-10 · Cited by 153
“The most clinically important phenotype of Candida biofilm cells is their remarkable resistance to antifungal drugs (1, 4, 17, 29, 39).”
BackgroundSelf-citationMolecular and Cellular Mechanisms That Lead to Candida Biofilm Formation
ten Cate, J. M., Klis, F. M., Pereira-Cenci, T., Crielaard, W., & de Groot, P. W. J. (2009) · Journal of Dental Research · doi:10.1177/0022034508329273 · Cited by 149
Liu, S., Hou, Y., Chen, X., Gao, Y., Li, H., & Sun, S. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.12.009 · Cited by 164
Tackling Fungal Resistance by Biofilm Inhibitors
Wu, S., Wang, Y., Liu, N., Dong, G., & Sheng, C. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01203 · Cited by 132
Ahmad, A., Khan, A., & Manzoor, N. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.09.016 · Cited by 144
Fan, F., Liu, Y., Liu, Y., Lv, R., Sun, W., Ding, W., Cai, Y., Li, W., Liu, X., & Qu, W. (2022) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2022.106673 · Cited by 159
Van Dijck, P., Sjollema, J., Camue, B. P. A., Lagrou, K., Berman, J., d’Enfert, C., Andes, D. R., Arendrup, M. C., Brakhage, A. A., Calderone, R., et al. (2018) · Microbial Cell · doi:10.15698/mic2018.07.638 · Cited by 129
Self-citationSamber, N., Khan, A., Varma, A. K., & Manzoor, N. (2015) · Pharmaceutical Biology · doi:10.3109/13880209.2014.989623 · Cited by 151
Sharma, M., Manoharlal, R., Negi, A. S., & Prasad, R. (2010) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2010.00637.x · Cited by 126
In vitro synergy of eugenol and methyleugenol with fluconazole against clinical Candida isolates
Ahmad, A., Khan, A., Khan, L. A., & Manzoor, N. (2010) · Journal of Medical Microbiology · doi:10.1099/jmm.0.020693-0 · Cited by 125
Pierce, C. G., Chaturvedi, A. K., Lazzell, A. L., Powell, A. T., Saville, S. P., McHardy, S. F., & Lopez-Ribot, J. L. (2015) · npj Biofilms and Microbiomes · doi:10.1038/npjbiofilms.2015.12 · Cited by 124
Overcoming antifungal resistance
Srinivasan, A., Lopez-Ribot, J. L., & Ramasubramanian, A. K. (2014) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2014.02.005 · Cited by 144
Lara, H. H., Ixtepan-Turrent, L., Jose Yacaman, M., & Lopez-Ribot, J. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b20708 · Cited by 116
Romo, J. A., Pierce, C. G., Chaturvedi, A. K., Lazzell, A. L., McHardy, S. F., Saville, S. P., & Lopez-Ribot, J. L. (2017) · mBio · doi:10.1128/mbio.01991-17 · Cited by 105
Calcineurin controls drug tolerance, hyphal growth, and virulence in Candida dubliniensis
Chen, Y.-L., Brand, A., Morrison, E. L., Silao, F. G. S., Bigol, U. G., Malbas, F. F., Nett, J. E., Andes, D. R., Solis, N. V., Filler, S. G., et al. (2011) · Eukaryotic Cell · doi:10.1128/ec.00310-10 · Cited by 107
Self-citationKatragkou, A., Kruhlak, M. J., Simitsopoulou, M., Chatzimoschou, A., Taparkou, A., Cotten, C. J., Paliogianni, F., Diza‐Mataftsi, E., Tsantali, C., Walsh, T. J., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/652783 · Cited by 102
Gong, Y., Li, T., Yu, C., & Sun, S. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00520 · Cited by 102
Amber, K., Aijaz, A. W., Immaculata, X., Luqman, K. A., & Nikhat, M. (2010) · Phytomedicine · doi:10.1016/j.phymed.2010.02.012 · Cited by 111
Genetic and Genomic Architecture of the Evolution of Resistance to Antifungal Drug Combinations
Hill, J. A., Ammar, R., Torti, D., Nislow, C., & Cowen, L. E. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003390 · Cited by 93
Antifungal Compounds against Candida Infections from Traditional Chinese Medicine
Liu, X., Ma, Z., Zhang, J., & Yang, L. (2017) · BioMed Research International · doi:10.1155/2017/4614183 · Cited by 91
Guo, N., Liu, J., Wu, X., Bi, X., Meng, R., Wang, X., Xiang, H., Deng, X., & Yu, L. (2009) · Journal of Medical Microbiology · doi:10.1099/jmm.0.008052-0 · Cited by 89
The role of Candida albicans stress response pathways in antifungal tolerance and resistance
Iyer, K. R., Robbins, N., & Cowen, L. E. (2022) · iScience · doi:10.1016/j.isci.2022.103953 · Cited by 88
Kato, I. T., Prates, R. A., Sabino, C. P., Fuchs, B. B., Tegos, G. P., Mylonakis, E. E., Hamblin, M. R., & Ribeiro, M. S. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01451-12 · Cited by 97
Candida albicans targets that potentially synergize with fluconazole
Lu, H., Shrivastava, M., Whiteway, M., & Jiang, Y. (2021) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2021.1884641 · Cited by 81
Plasticity of Candida albicans Biofilms
Soll, D. R., & Daniels, K. J. (2016) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00068-15 · Cited by 78
Future directions for anti-biofilm therapeutics targetingCandida
Nett, J. E. (2014) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2014.885838 · Cited by 95
Self-citationWang (2009) · Oncology Reports · doi:10.3892/or_00000539 · Cited by 80
Lee, J., Kim, Y., Khadke, S. K., Yamano, A., Watanabe, A., & Lee, J. (2019) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00033 · Cited by 73
Uppuluri, P., Chaturvedi, A. K., & Lopez-Ribot, J. L. (2009) · Mycopathologia · doi:10.1007/s11046-009-9205-9 · Cited by 70
Self-citationAlexidine Dihydrochloride Has Broad-Spectrum Activities against Diverse Fungal Pathogens
Mamouei, Z., Alqarihi, A., Singh, S., Xu, S., Mansour, M. K., Ibrahim, A. S., & Uppuluri, P. (2018) · mSphere · doi:10.1128/msphere.00539-18 · Cited by 70
Self-citationCombination Therapy to Treat Fungal Biofilm-Based Infections
Tits, J., Cammue, B. P. A., & Thevissen, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228873 · Cited by 69
Drug repurposing strategies in the development of potential antifungal agents
Zhang, Q., Liu, F., Zeng, M., Xin, C., Zhang, J., Mao, Y., & Song, Z. (2021) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-021-11407-7 · Cited by 82
Novel strategies to fightCandidaspecies infection
Rodrigues, M. E., Silva, S. M., Azeredo, J., & Henriques, M. (2014) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2014.974500 · Cited by 78
Synergistic and antagonistic drug interactions in the treatment of systemic fungal infections
Wambaugh, M. A., Denham, S. T., Ayala, M., Brammer, B., Stonhill, M. A., & Brown, J. C. (2020) · eLife · doi:10.7554/elife.54160 · Cited by 65
“Discussion Synergistic combination therapies are increasingly important clinical options, especially for drug resistant microbes (Cowen and Lindquist, 2005; Kalan and Wright, 2011; Uppuluri et al., 2008; Zheng et al., 2018).”
BackgroundBonincontro, G., Scuderi, S. A., Marino, A., & Simonetti, G. (2023) · Pharmaceuticals · doi:10.3390/ph16111531 · Cited by 91
Kumar, A., Alam, A., Grover, S., Pandey, S., Tripathi, D., Kumari, M., Rani, M., Singh, A. P., Akhter, Y., Ehtesham, N. Z., et al. (2019) · npj Biofilms and Microbiomes · doi:10.1038/s41522-018-0075-0 · Cited by 68
Rao, H., Choo, S., Mahalingam, S. R. R., Adisuri, D. S., Madhavan, P., Akim, A. M., & Chong, P. P. (2021) · Molecules · doi:10.3390/molecules26071870 · Cited by 73
New antifungal strategies: Drug combination and co-delivery
Zhu, P., Li, Y., Guo, T., Liu, S., Tancer, R. J., Hu, C., Zhao, C., Xue, C., & Liao, G. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114874 · Cited by 63
Characteristics of Candida albicans Biofilms Grown in a Synthetic Urine Medium
Uppuluri, P., Dinakaran, H., Thomas, D. P., Chaturvedi, A. K., & Lopez-Ribot, J. L. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.01377-09 · Cited by 77
Self-citationYu, Q., Ding, X., Xu, N., Cheng, X., Qian, K., Zhang, B., Xing, L., & Li, M. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.10.009 · Cited by 64
Fungal Biofilms: In Vivo Models for Discovery of Anti-Biofilm Drugs
Nett, J. E., & R. Andes, D. (2015) · Microbiology Spectrum · doi:10.1128/microbiolspec.mb-0008-2014 · Cited by 60
Self-citationShekhar-Guturja, T., Tebung, W. A., Mount, H., Liu, N., Köhler, J. R., Whiteway, M., & Cowen, L. E. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01959-16 · Cited by 59
In Vitro and In Vivo Assessment of FK506 Analogs as Novel Antifungal Drug Candidates
Lee, Y., Lee, K.-T., Lee, S. J., Beom, J. Y., Hwangbo, A., Jung, J. A., Song, M. C., Yoo, Y. J., Kang, S. H., Averette, A. F., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01627-18 · Cited by 58
Self-citationVirulence and Biofilms As Promising Targets in Developing Antipathogenic Drugs Against Candidiasis
Khan, M. S., Alshehrei, F. M., Alghamdi, S., Bamaga, M. A., Althubiani, A. S., & Alam, M. Z. (2020) · Future Science OA · doi:10.2144/fsoa-2019-0027 · Cited by 70
Cordeiro, R. D. A., Teixeira, C. E. C., Brilhante, R. S. N., Castelo‐Branco, D. D. S. C. M., de Alencar, L. P., de Oliveira, J. S., Monteiro, A. J., Bandeira, T. J. P. G., Sidrim, J. J. C., Moreira, J. L. B., et al. (2015) · FEMS Yeast Research · doi:10.1093/femsyr/fov012 · Cited by 67
The Clinical Importance of Fungal Biofilms
Ramage, G., & Williams, C. (2013) · Advances in applied microbiology · doi:10.1016/b978-0-12-407673-0.00002-3 · Cited by 62
Augmenting Azoles with Drug Synergy to Expand the Antifungal Toolbox
Kane, A., & Carter, D. A. (2022) · Pharmaceuticals · doi:10.3390/ph15040482 · Cited by 58
Potential Targets for Antifungal Drug Discovery Based on Growth and Virulence in Candida albicans
Li, X., Hou, Y., Yue, L., Liu, S., Du, J., & Sun, S. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00726-15 · Cited by 54
Sensitization of Candida albicans biofilms to various antifungal drugs by cyclosporine A
Shinde, R. B., Chauhan, N. M., Raut, J. S., & Karuppayil, S. M. (2012) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/1476-0711-11-27 · Cited by 59
In Vitro Interactions between Antifungals and Immunosuppressive Drugs against Zygomycetes
Dannaoui, E., Schwarz, P., & Lortholary, O. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00184-09 · Cited by 54
Jia, W., Zhang, H., Li, C., Li, G., Liu, X., & Wei, J. (2016) · BMC Microbiology · doi:10.1186/s12866-016-0728-1 · Cited by 52
Anti-Biofilm Strategies: How to Eradicate Candida Biofilms?
Bink, A. (2011) · The Open Mycology Journal · doi:10.2174/1874437001105010029 · Cited by 51
Carmello, J. C., Alves, F., Basso, F. G., Costa, C. A. D. S., Tedesco, A. C., Primo, F. L., Mima, E. G. D. O., & Pavarina, A. C. (2019) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2019.06.010 · Cited by 55
Guo, N., Wu, X., Yu, L., Liu, J., Meng, R., Jin, J., Lu, H., Wang, X., Yan, S., & Deng, X. (2009) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.2009.00620.x · Cited by 52
Calcium-calcineurin signaling pathway in Candida albicans: A potential drug target
Li, W., Shrivastava, M., Lu, H., & Jiang, Y. (2021) · Microbiological Research · doi:10.1016/j.micres.2021.126786 · Cited by 47
Revie, N. M., Iyer, K. R., Maxson, M. E., Zhang, J., Yan, S., Fernandes, C. M., Meyer, K. J., Chen, X., Skulska, I., Fogal, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31308-1 · Cited by 57
Self-citationChloroquine sensitizes biofilms of Candida albicans to antifungal azoles
Shinde, R. B., Raut, J. S., Chauhan, N. M., & Karuppayil, S. M. (2013) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2012.11.002 · Cited by 47
Zhang, H., Guo, J., Voegele, R. T., Zhang, J., Duan, Y., Luo, H., & Kang, Z. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049262 · Cited by 48
Role of the extracellular matrix in Candida biofilm antifungal resistance
Massey, J., Żarnowski, R., & Andes, D. R. (2023) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuad059 · Cited by 52
Self-citationCao, C., Wang, Y., Husain, S., Soteropoulos, P., & Xue, C. (2019) · mBio · doi:10.1128/mbio.01952-19 · Cited by 53
Novel Antifungal Agents and Their Activity against Aspergillus Species
Vahedi‐Shahandashti, R., & Lass‐Flörl, C. (2020) · Journal of Fungi · doi:10.3390/jof6040213 · Cited by 51
Chen, S. C.-A., Lewis, R. E., & Kontoyiannis, D. P. (2011) · Virulence · doi:10.4161/viru.2.4.16764 · Cited by 41
High-Throughput Nano-Biofilm Microarray for Antifungal Drug Discovery
Srinivasan, A., Leung, K. P., Lopez-Ribot, J. L., & Ramasubramanian, A. K. (2013) · mBio · doi:10.1128/mbio.00331-13 · Cited by 41
Fluconazole-COX Inhibitor Hybrids: A Dual-Acting Class of Antifungal Azoles
Elias, R., Basu, P., & Fridman, M. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01807 · Cited by 40
Gao, Y., Zhang, C., Lu, C., Liu, P., Li, Y., Li, H., & Sun, S. (2013) · FEMS Yeast Research · doi:10.1111/1567-1364.12048 · Cited by 39
Egan, J. D., García-Pedrajas, M. D., Andrews, D. L., & Gold, S. E. (2009) · Molecular Plant-Microbe Interactions® · doi:10.1094/mpmi-22-10-1293 · Cited by 39
de Barros, P. P., Rossoni, R. D., Garcia, M. T., Kaminski, V. D. L., Loures, F. V., Fuchs, B. B., Mylonakis, E. E., & Junqueira, J. C. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.700305 · Cited by 45
Toenjes, K. A., Stark, B. C., Brooks, K. M., & Johnson, D. I. (2009) · Journal of Medical Microbiology · doi:10.1099/jmm.0.006841-0 · Cited by 37
Lara, H. H., & Lopez-Ribot, J. L. (2020) · Pathogens · doi:10.3390/pathogens9100784 · Cited by 36
In Vitro Study of Sequential Fluconazole and Caspofungin Treatment against Candida albicans Biofilms
Sarkar, S., Uppuluri, P., Pierce, C. G., & Lopez-Ribot, J. L. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01745-13 · Cited by 41
Self-citationChang, W., Li, Y., Zhang, L., Cheng, A., Liu, Y., & Lou, H. (2012) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b12-00511 · Cited by 36
Cordeiro, R. D. A., Macêdo, R. D. B., Teixeira, C. E. C., Marques, F. J. D. F., Bandeira, T. D. J. P. G., Moreira, J. L. B., Brilhante, R. S. N., Rocha, M. F. G., & Sidrim, J. J. C. (2014) · Journal of Medical Microbiology · doi:10.1099/jmm.0.073478-0 · Cited by 38
Regulatory roles of phosphorylation in model and pathogenic fungi
Bataineh, M. T. A., & Kadosh, D. (2015) · Medical Mycology · doi:10.1093/mmy/myv098 · Cited by 38
Li, Y., Chang, W., Zhang, M., Li, X., Jiao, Y., & Lou, H. (2015) · FEMS Yeast Research · doi:10.1093/femsyr/fov001 · Cited by 36
From Biology to Drug Development: New Approaches to Combat the Threat of Fungal Biofilms
Pierce, C. G., Srinivasan, A., Ramasubramanian, A. K., & Lopez-Ribot, J. L. (2015) · Microbiology Spectrum · doi:10.1128/microbiolspec.mb-0007-2014 · Cited by 42
Liu, Y., Ren, H., Wang, D., Zhang, M., Sun, S., & Zhao, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110580 · Cited by 37
Metadata
- Authors
- Uppuluri, P., Nett, J., Heitman, J., & Andes, D.
- Affiliations
- Duke Medical Center (US)
- University of Wisconsin–Madison (US)
- Corresponding author
- Heitman, Joseph
- Andes, David
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2008-03
- Volume
- 52
- Issue
- 3
- Pages
- 1127-1132
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC2258509
- OpenAlex
- W2127992552
- Cited by
- 228
- References
- 40
- Citations by year
- 2026: 9 · 2025: 11 · 2024: 5 · 2023: 10 · 2022: 10 · 2021: 13 · 2020: 14 · 2019: 13 · 2018: 9 · 2017: 14 · 2016: 14 · 2015: 19 · 2014: 16 · 2013: 17 · 2012: 18
- FWCI
- 7.71
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (NIH-R01)
- Department of Biology, Duke University
- National Heart, Lung, and Blood Institute (T32HL007899)
- National Institute of Allergy and Infectious Diseases (R01AI042159, R01AI42159, R01 AI50438, R01AI050438)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bacterial biofilms and quorum sensing
- Keywords
- Candida albicans, biofilm, calcineurin, calcineurin inhibitors, FK506, cyclosporine, fluconazole, drug synergy, antifungal resistance, azole antifungals, ergosterol biosynthesis, membrane perturbation, FKBP12, catheter-related infection, combination therapy
- MeSH terms
- Animals, Antifungal Agents, Candida albicans, Drug Synergism, Humans, Microbial Sensitivity Tests, Fluconazole, Tacrolimus, Cyclosporine, Biofilms, Drug Resistance, Fungal, Rats, Calcineurin Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.